Skip to content

Esketamine for depression: all studies

Page 57 of 57: studies 561 to 564 of 564, newest first. Back to the esketamine for depression overview

Research

Esketamine rapid antidepression combined with dexmedetomidine sleep modulation for patients with depression and insomnia

Muyan Zuo, Yaozu Li, John P Williams et al. preprint

Purpose: Depression combined with insomnia is a complex bidirectional relationship that is more difficult to treat versus a single disorder, and there is a lack of effective treatments available. In this study, we carried out a novel way to simultaneously intervene in depression combined with insomnia and examined functional magnetic resonance imaging (fMRI) to help further elucidate the...

Effect of esketamine on postpartum depression and pain control after caesarean section: A randomized, double-blind, controlled clinical trial

Shurong Li, Zhifang Zhuo, Renwei Li et al. preprint

Abstract Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section....

Intranasal Esketamine for Treating Inpatients with Borderline Personality Disorder and Comorbid Treatment-Resistant Depression – a Retrospective Chart Review Study

Hannah Tramontano, Jeffrey Fetter, Mohamed Wagdy ElSayed preprint

Background: Borderline Personality Disorder (BPD) affects 1.35% of the population and is frequently comorbid with Major Depressive Disorder (MDD), which is frequently treatment-resistant (TRD). Patients with comorbid illness have worse treatment outcomes and functional impairment. Esketamine could ameliorate symptoms of both illnesses. Methods: We conducted a retrospective chart review of...

Esketamine-induced dentate gyrus plasticity in treatment resistant depression: First-in-human evidence

Research Square Alice Le Berre preprint

Abstract Background: Treatment-resistant depression (TRD) involves impaired hippocampal plasticity. Preclinical work showed synaptic potentiation and dendritic spine growth in the dentate gyrus (DG) after esketamine (ESK), but human evidence is lacking. We aimed to detect early DG changes after ESK using advanced diffusion MRI, and to test whether baseline MRI metrics predict clinical response....